Novel oral anticoagulants (NOACs) are safe and effective for the prevention of stroke or
systemic embolism (S/SE) in atrial fibrillation. The efficacy and safety of NOACs compared …

Objective To investigate the relative effect of warfarin versus non-vitamin K oral
anticoagulants (NOACs) in thrombotic and bleeding outcomes in subgroups of atrial …

Introduction We performed a meta-analysis of the safety and efficacy of anticoagulation
treatment for atrial fibrillation (AF) in relation to renal function. We also examined the change …

Background Non‐vitamin K antagonist oral anticoagulants (NOACs) have better
pharmacologic properties than warfarin and are recommended in preference to warfarin in …

Background: Patients with atrial fibrillation and severely decreased kidney function were
excluded from the pivotal non–vitamin K antagonist oral anticoagulants (NOAC) trials …

Background Patients with warfarin have a potential risk of warfarin-related nephropathy,
which could result in the discontinuation of anticoagulation therapy. The question of whether …

Background: Lifelong oral anticoagulation, either with warfarin or a non–vitamin K
antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with …

Renal impairment increases risk of stroke and systemic embolic events and bleeding in
patients with atrial fibrillation. Direct oral anticoagulants (DOACs) have varied dependence …

Aims We aimed to compare the efficacy and safety between non-vitamin K antagonist oral
anticoagulants (NOACs) and warfarin in atrial fibrillation (AF) patients according to renal …

Objectives: This study investigated the efficacy and safety of novel oral anticoagulants
(NOACs) in patients with atrial fibrillation (AF) and heart failure (HF) by a meta-analysis …